Double CAR-T attack on rare blood cancer shows promise
NCT ID NCT05870917
Summary
This study is testing whether adding two rounds of CAR-T cell therapy to standard chemotherapy and a stem cell transplant can better control a rare and aggressive blood cancer called plasma cell leukemia. The treatment involves initial chemotherapy, followed by CAR-T cells, more chemotherapy, a stem cell transplant, then a second CAR-T infusion. Researchers want to see if this combination approach is safe and effective for newly diagnosed patients who haven't had previous treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.